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Dyslipidaemia
Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis 
and has become a permanently evolving area of clinical interest. Scientific 
societies periodically publish international guidelines for use as 
recommendations for daily practice in different regions of the world.1 
Dyslipidaemia is a constantly changing field as a consequence of advances 
in understanding of the pathophysiological mechanisms of the relationship 
between lipid metabolism and atherogenesis, along with the development 
of new, potent, lipid-lowering therapies.2,3 Thus, concepts such as 
atherogenic dyslipidaemia or residual risk have become common subjects 
of analysis in the recent medical literature.4 Beyond LDL cholesterol, 
suboptimal levels of other atherogenic lipids and lipoproteins – including 
triglycerides, HDL cholesterol, non-HDL cholesterol (total cholesterol minus 
HDL cholesterol) and apolipoprotein B – also play a role.5 
Statin Therapy: The Gap Between Guidelines 
and Real-world Clinical Practice
Statins, ezetimibe, the birth of proprotein convertase subtilisin/kexin type 
9 (PCSK9) inhibitors and the rebirth of fibrates and omega 3 fatty acid 
therapies, have contributed to debate about the gap between theoretical 
guidelines and clinical practice in the real world. The recently published 
EUROASPIRE V survey showed that a large majority of patients in primary 
care at high cardiovascular risk failed to achieve the lifestyle, blood 
pressure, lipid and glycaemic targets defined in the 2016 joint European 
societies’ guidelines, illustrating the wide gap that still exists.6 Despite the 
powerful concept of high cardiovascular risk in terms of mortality and 
events and the importance of achieving lipid goals, gaps in dyslipidaemia 
care have been reported among patients with established cardiovascular 
disease (CVD).7,8
Okerson et al. conducted a retrospective cohort study in 90,287 patients 
in the US with a diagnosis of clinical atherosclerotic CVD (ASCVD).9 The 
aim of the study was to evaluate the impact on clinical practice of the 2013 
American College of Cardiology (ACC)/American Heart Association (AHA) 
guidelines.9 Their main finding was that statin use remained the same 
before and after the publication of the guidelines. There were no changes 
in mean LDL cholesterol levels. In patients who had received high-
intensity statins, statin use increased by 4% 1 year after the guidelines 
(p<0.001).  In addition to these poor preliminary data, there was also 
criticism towards the guidelines as they changed the main concept: LDL 
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targeting to treatment based on the level of risk, and of the fact that the 
score proposed by the AHA/ACC overestimated the risk in regions outside 
the US.10 However, many years later, we have recognized the main 
contribution of guidelines.
Statins are recommended by the UK’s National Institute for Health and 
Care Excellence (NICE) as first-line lipid-modifying therapy for the 
reduction of cardiovascular event risk in patients with ASCVD, as well as 
diabetes, familial hypercholesterolaemia, chronic kidney disease and 
other high-risk primary-prevention populations.11 Taking into consideration 
the availability of generic atorvastatin, the NICE guidelines recommended 
atorvastatin 80 mg for patients with ASCVD and atorvastatin ≥20 mg for 
those with most other high-risk conditions. However, in a cohort study that 
included 91,479 patients with ASCVD, 21% did not receive any statin and 
only 31% received a high-intensity statin.12 Up to 94% of patients with 
ASCVD and 85% of high-risk non-ASCVD individuals – representing 
approximately 3 million individuals in each group in the UK – would 
require statin up-titration or initiation to achieve full concordance with 
updated guidelines.
The REPAR study was a multicentre, prospective observational study in 
Spain including 1,103 patients with stable coronary heart disease.13 Only 
26% of patients had LDL cholesterol <1.8 mmol/l, while 55% received 
low- or moderate-intensity statin therapy. When patients had LDL 
cholesterol values >1.8 mmol/l the attitude of physicians was passive. 
Over 70% made no changes, 26% increased treatment and 3% 
decreased it. The authors identified differences according to age of 
physicians – with a more proactive attitude in older doctors – and by 
region, unrelated to patient profile. 
Problems in achieving lipid goals and applying guideline recommendations 
are not restricted to European and North American countries. The PURE 
study reported a low proportion of patients with coronary artery disease 
or antecedent of stroke treated with statins in South America (18% and 
9.8%, respectively) and in South Asia (4.8% and 0.6%, respectively).14,15 
The cross-sectional observational ICLPS was conducted in 452 centres 
in 18 countries in Eastern Europe, Asia, Africa, the Middle East and Latin 
America, recruiting more than 9,000 patients.16 Patients who had been 
receiving a stable dose and type of lipid-lowering therapy for ≥3 months 
before enrolment and had their LDL cholesterol value measured while 
receiving stable lipid-lowering therapy in the previous 12 months were 
eligible. The percentage of patients who achieved the relevant target 
goals was 51.4% when estimated by physicians versus 39.9% when 
based on European Society of Cardiology (ESC)/European Atherosclerosis 
Society recommendations (p<0.001), demonstrating an important gap 
between guidelines and clinical practice. Overall findings in patients 
receiving stable lipid-lowering therapy from countries outside western 
Europe suggest that approximately one-third of very-high-risk patients 
and half of high-risk patients achieve their risk-based target goals, 
whereas over half to two-thirds of moderate-risk patients achieve 
their goal.
Evidence supports the importance of the use of ezetimibe added to statin 
therapy to achieve goals and reduce events and cardiovascular risk. The 
results of the landmark IMPROVE-IT indicated that after acute coronary 
syndrome, ezetimibe 10 mg/simvastatin 40 mg was superior to simvastatin 
40 mg alone in reducing cardiovascular events in high-risk patients.17 A 
reduction of recurrent events was observed. Patients with diabetes, prior 
stroke and prior coronary artery bypass graft appeared to have a greater 
treatment effect from ezetimibe than patients without diabetes. However, 
ezetimibe prescription is still lower than expected. 
In the FOURIER study population, 27,564 patients with established CVD 
and at least one major risk factor (diabetes, current smoking, age ≥65 
years, MI or non-haemorrhagic stroke, or symptomatic peripheral artery 
disease) were treated with lipid-lowering therapy.18 At baseline, only 1,440 
(5.3%) were receiving ezetimibe. 
More recently, the REDUCE-IT trial randomised 8,179 statin-treated 
patients with elevated triglycerides (≥3.5 mmol/l and <13 mmol/l), LDL 
cholesterol (>1.0 mmol/l and ≤2.6 mmol/l) and a history of atherosclerosis 
(71% of patients) or diabetes (29% patientsof ) to icosapent ethyl 4 g/day 
or placebo.19 Only 6.4% of patients were given ezetimibe. 
The VIPFARMA ISCP Project
Apart from statin intensity and LDL cholesterol goals, there are some 
aspects of atherogenic dyslipidaemia that are often neglected.20 It is well 
known that atherogenic dyslipidaemia is associated with poor 
cardiovascular outcomes, but markers of this condition, such as 
triglycerides, are often ignored in clinical practice.21
Some aspects explain the barriers to implementing recommendations 
from guidelines into clinical practice worldwide. A decade ago, Erhardt et 
al. grouped the components of non-adherence into patient, physician and 
medication-related reasons.22 In order to improve continuing medical 
education programmes, it is essential to understand causes that relate to 
clinician attitudes. This underpins the rationale for the International 
Society of Cardiovascular Pharmacotherapy (ISCP) Surveillance of 
Prescription Drugs in the Real World Project (VIPFARMA ISCP; Figure 1). 
Aim
The aim of the VIPFARMA ISCP survey is to obtain relevant and 
representative data on a specific population regarding prescriptions or 
adherence to pharmacological therapeutic protocols. In the first stage, 






• Medical-related reasons 
VIPFARMA project:
• 1,000 surveys 
• Population: cardiologists, 
  clinicians and others 
• Seven clusters of questions 
• Demographics
• Institution and city profile
• Access to continuing medical education
• Clinical practice profile
• Attitudes regarding statins
• Knowledge regarding PCSK9 inhibitors
• Attitudes regarding triglycerides
Figure 1: The VIPFARMA ISCP Project 
Main barriers to the translation of guideline recommendations into clinical practice and 
the seven clusters of questions in the survey. PCSK9 = proprotein convertase subtilisin/kexin 
type 9.
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The pilot research will be conducted by the Argentinean chapter of the 
ISCP. Because updated Argentinean guidelines are yet to be published, the 
ESC 2019 recommendations will be used as a reference.23 While lifestyle 
habits regarding dyslipidaemia are recognised as crucially important, this 
study will focus on medical attitudes towards lipid-lowering drug therapies. 
Methods
Study Design
A cross-sectional online survey will be submitted to doctors in different 
specialties (internal medicine, cardiology, endocrinology, general 
medicine or other) who usually treat patients with dyslipidaemia in the 
range of 1–10 patients per week. Participants specify their sub-specialty 
when responding (preventive medicine, preventive cardiology, diabetes, 
arterial hypertension or other). Our research team will send personal 
invitations to peers and will post open invitations on social media. The 
pilot study aims to reach 1,000 returned surveys in Argentina. Reminders 
will also be sent.
The questionnaire will include 30 questions with dichotomous, Likert-
scale, rank-order, and open-ended response choices (Supplementary 
Material Appendix 1). Questions will not be compulsory and respondents 
will be permitted to select multiple response choices depending on the 
question content.
Statistical Analysis
Data will be collected via Google Forms and exported to SPSS (version 
24.0; IBM) for statistical analysis. Means and SD will be used for continuous 
variables and frequencies and percentages for categorical variables. 
Independent sample t-tests will be used to compare the normally 
distributed continuous variables, the Mann–Whitney U test will be used 
for non-normally distributed continuous variables, and the Pearson 
χ-squared test (or the Fisher’s Exact test, as appropriate) for categorical 
variables. A p value <0.05 will be considered statistically significant.
Survey Content and Rationale
Demographics
This cluster of questions focuses on age, sex, number of years of practice, 
specialty and subspecialty. The PERCRO-DOC survey, conducted among 
1,382 randomly selected physicians (general practitioners/family medicine 
specialists, internists and cardiologists) from different regions of Croatia, 
showed that primary care physicians generally use their own personal 
experience in prevention, while internists and cardiologists are more 
likely to use guidelines.24 
Another aspect we will ask about is the possible influence of pharmaceutical 
marketing on the dissemination of guideline content and about the use of 
new drugs.25 In 2019, the ESC board published a position statement that 
highlighted the changes resulting from its new Codes of Practice for the 
Pharmaceutical and Medical Device Industry.26 Consequently, access to 
scientific updates could probably be facilitated in specific subgroups.
Institution and City Profile
The PURE study demonstrated clear differences between urban and rural 
populations regarding cardiovascular prevention treatments.27 Therefore, 
it is relevant to analyse the differences in attitude and knowledge of 
doctors according to institution characteristics, the size of their cities 
where they work and the geographical location. Disparities in access to 
training and education of healthcare professionals, in conjunction with 
societal factors, may contribute to significant differences in morbidity and 
mortality from CVD in cities and provinces of the same country.28
Access to Continuing Medical Education
Clinicians in today’s healthcare environment face an overwhelming volume 
of information, which requires continued education and lifelong learning. In 
order to determine access to continuing medical education, questions focus 
on academy activities, subscription to medical journals and recent reading 
of scientific articles. A Cochrane review of educational meetings examined 
81 randomised controlled trials and  concluded that there are differences in 
the improvement of professional practice and the health outcomes of 
patients according to the type of educational activity to which healthcare 
professionals have access.29 Nissen et al. demanded changes in the 
continuing medical education system due to the accelerating rate of change 
in medical knowledge, which represents an enormous challenge to 
physicians’ ability to offer patients high-quality care.30,31 Barriers to access 
these new educational platforms can determine different degrees of 
knowledge and application of the guidelines in clinical practice.
Clinical Practice Profile 
These questions aim to determine the experience in the management of 
patients with two types of lipid disorders, both of which involve a high 
cardiovascular risk condition: familial hypercholesterolemia and atherogenic 
dyslipidaemia in secondary prevention patients. The first is usually under 
diagnosed and the second is associated with inadequate treatment.32,33 
In particular, early identification of familial hypercholesterolaemia is 
important for the prevention of coronary artery disease.34 Frequency of care 
in this group of patients could determine professional behaviour in terms 
of the goal level to be proposed and the intensity of the treatments they 
will be comfortable to indicate.35 The experience of the physician may 
possibly be reflected in the type of decisions that they take in specific 
patients, such as those with familial dyslipidaemia.36
Attitudes Regarding Statins 
Despite the large and consistent body of evidence on the benefits of 
statins in primary and secondary prevention, their proper use continues to 
be a huge challenge for public health.37,38 Misconceptions lead to medical 
decisions with undesirable consequences, such as non-adherence to 
treatment, insufficient doses or failure to reach goals. For this reason, 
these questions will ask about the clinicians’ experience of adverse 
effects and the combination of statins with other drugs, such as ezetimibe.17
Knowledge Regarding PCSK9 Inhibitors 
Understanding of PCSK9 has revolutionised the management of 
dyslipidaemia and has prompted research into monoclonal antibodies 
that inhibit it, such as alirocumab and evolocumab.39,40 While these drugs 
are included in the new guidelines, the opinion of physicians on these 
high-cost biological drugs is unknown, particularly regarding the very low 
LDL cholesterol fraction that can be achieved. In the FOURIER trial, 48-
week outcomes showed that LDL cholesterol level in the evolocumab 
group was reduced to ≤1.8 mmol/l in 87% of patients, to ≤1.0 mmol/l in 
67% of patients and to ≤0.65 mmol/l in 42% of patients. This compared 
with 18%, 0.5%, and <0.1%, respectively, in patients in the placebo group 
(p<0.001 for all comparisons, evolocumab versus placebo). The questions 
in this cluster are designed to establish the level of confidence and any 
concerns that physicians have regarding the use of these drugs.41
Attitudes Regarding Triglycerides 
The final cluster of questions will address the attitude of physicians 
towards the interpretation and management of elevated triglycerides. It is 
now established that omega-3 and omega-6 fatty acids play important 
roles in human health and disease. Recent results from REDUCE-IT have 
impacted medical opinion because it addressed residual risk, finding a 
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significant 25% relative risk reduction in first ischaemic events using 
icosapent ethyl 4 g daily versus placebo in statin-treated patients with 
triglycerides ≥135 mg/dl.42 Finally, we will ask about cut-off values to treat 
hypertriglyceridaemia and prescribing of fibrates or omega 3 fatty acids.
Conclusion
Dyslipidaemia plays a critical role in the pathogenesis of atherosclerosis. 
Proper pharmacological management of lipid disorders, especially familial 
and atherogenic dyslipidaemia, constitutes one of the greatest challenges 
in cardiovascular prevention in high-risk patients. However, some medical 
barriers prevent patients from achieving goals, contributing to the perceived 
gap between guidelines and daily clinical practice. It is therefore relevant to 
determine the attitudes of physicians regarding lipid management. The 
results of the VIPFARMA ISCP project will allow the identification of obstacles 
that exist in the medical community and the setting of an agenda to improve 
continuing medical education programmes. 
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